이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Safety and Clinical Performance of the Next-Generation SAFESYNC Transcatheter Heart Valve in Patients With Severe Aortic Stenosis (SAFESYNC NG)

2026년 11월 16일 업데이트: Braile Biomedica Ind. Com. e Repr. Ltda.

Evaluation of the Safety and Clinical Performance of the Next-Generation SAFESYNC Balloon-Expandable Transcatheter Heart Valve in Patients With Severe Aortic Stenosis: A Prospective, Multicenter, Single-Arm Pivotal Study

This pivotal, prospective, multicenter (Brazil, Chile and Argentina), single-arm study will evaluate the safety and clinical performance of the Inovare® Safesync Next-Generation bioprosthetic heart valve, implanted by transfemoral transcatheter aortic valve implantation (TAVI) with the B-Delivery System, in patients aged 70 years or older with severe aortic stenosis and an indication for TAVI, regardless of surgical risk. The study will enroll 210 participants.

연구 개요

연구 유형

중재적

등록 (추정된)

210

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: Clinical Research Department - Braile Biomédica
  • 전화번호: +5517 21367000
  • 이메일: pesquisa@braile.com.br

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

70년 이상 (고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

Severe aortic valve stenosis diagnosed according to criteria established in current guidelines; Age ≥70 years, regardless of surgical risk; Indication for transcatheter aortic valve implantation (TAVI); Willing to participate and to sign the written informed consent form.

Exclusion Criteria:

Any condition considered a contraindication to implantation of a bioprosthetic heart valve (e.g., patient with an indication for a mechanical heart valve);

Known hypersensitivity or contraindication to any of the following that cannot be adequately managed with premedication:

  1. Aspirin, clopidogrel, or heparin (heparin-induced thrombocytopenia [HIT] or heparin-induced thrombocytopenia with thrombosis [HITTS]);
  2. Nitinol (titanium or nickel);
  3. Contrast media; Blood dyscrasias: leukopenia (white blood cell count <1,000/mm³), thrombocytopenia (platelet count <100,000 cells/mm³), history of coagulopathy, or hypercoagulable states; Active infection, including endocarditis; Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or need for mechanical hemodynamic support; Recent stroke or transient ischemic attack (within 6 months); History of gastrointestinal bleeding or other bleeding that precludes anticoagulant or antiplatelet therapy; Estimated life expectancy of less than 5 years; Other medical, social, or psychological conditions that, in the investigator's opinion, prevent the patient from providing consent or adequately complying with the protocol; Pre-existing prosthetic heart valve in the aortic position (biological or mechanical); Concomitant severe mitral or tricuspid valve disease; Hypertrophic obstructive cardiomyopathy; Percutaneous coronary intervention performed within 72 hours prior to the study procedure; Femoral artery diameter <5.5 mm (for Safesync 20 to 24 mm), <6.0 mm (for Safesync 26 and 28 mm), or <6.5 mm (for Safesync 30 mm); High risk of annular rupture or significant residual paravalvular leak due to severe calcification of the aortic valve or left ventricular outflow tract; High risk of coronary obstruction (coronary ostial height <10 mm with narrow sinuses of Valsalva [SOV], defined as a mean SOV diameter <3 mm larger than the bioprosthesis size), as determined by computed tomography angiography; Left ventricular dysfunction with left ventricular ejection fraction (LVEF) ≤30%; Severe chronic kidney disease, defined as glomerular filtration rate <30 mL/min/1.73 m².

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: INOVARE® SAFESYNC Next-Generation TAVI

Participants will undergo TAVI via transfemoral access using the INOVARE® SAFESYNC Next-Generation Bioprosthetic Heart Valve and the B-Delivery System.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Device Success According to VARC-3 Criteria
기간: 30 days after the procedure

Technical success; Absence of mortality; Absence of surgery or intervention related to the device or to major vascular, access-related, or cardiac structural complications; Intended valve performance, defined as mean transvalvular gradient <20 mmHg, peak velocity <3 m/s, Doppler velocity index ≥0.25, and less than moderate aortic regurgitation.

30 days after the procedure

2차 결과 측정

결과 측정
측정값 설명
기간
Percentage of Participants Achieving Technical Success According to VARC-3 Criteria
기간: During the procedure

Defined as freedom from mortality; successful vascular access, delivery of the device, and retrieval of the delivery system; correct positioning of a single prosthetic heart valve in the intended anatomical location; and freedom from surgery or intervention related to the device or to a major vascular, access-related, or cardiac structural complication. Results will be reported as the number and percentage of participants achieving technical success.

During the procedure
Incidence and Severity of Paravalvular Leak
기간: 30 days, 6 months, 12 months, and annually through 5 years

Paravalvular leak will be assessed by transthoracic echocardiography and classified according to severity. The number and percentage of participants with paravalvular leak in each severity category will be reported.

30 days, 6 months, 12 months, and annually through 5 years
Mean Transvalvular Aortic Pressure Gradient Assessed
기간: 30 days, 6 months, 12 months, and annually through 5 years

Mean transvalvular aortic pressure gradient will be assessed by transthoracic echocardiography and reported in mmHg.

30 days, 6 months, 12 months, and annually through 5 years
Distribution of Participants by New York Heart Association Functional Class
기간: 30 days, 6 months, 12 months, and annually through 5 years

Functional status will be assessed using the New York Heart Association (NYHA) Functional Classification. The classification ranges from Class I to Class IV, where Class I represents no limitation of physical activity and Class IV represents inability to perform physical activity without symptoms and/or symptoms at rest. Higher NYHA classes indicate worse functional status. Results will be reported as the number and percentage of participants in each NYHA functional class.

30 days, 6 months, 12 months, and annually through 5 years
Incidence of New Permanent Pacemaker Implantation
기간: 30 days, 6 months, 12 months, and annually through 5 years

New permanent pacemaker implantation following the index transcatheter aortic valve implantation procedure will be assessed. Results will be reported as the number and percentage of participants who undergo new permanent pacemaker implantation.

30 days, 6 months, 12 months, and annually through 5 years
Incidence of All-Cause Mortality
기간: 30 days, 6 months, 12 months, and annually through 5 years

All-cause mortality will be assessed throughout follow-up. Results will be reported as the number and percentage of participants who die from any cause.

30 days, 6 months, 12 months, and annually through 5 years
Incidence of Stroke
기간: 30 days, 6 months, 12 months, and annually through 5 years

Stroke events will be assessed based on clinical neurological evaluation and classified according to Valve Academic Research Consortium 3 (VARC-3) definitions. Results will be reported as the number and percentage of participants experiencing stroke.

30 days, 6 months, 12 months, and annually through 5 years
Incidence of Bioprosthetic Valve-Related Reintervention
기간: 30 days, 6 months, 12 months, and annually through 5 years

Bioprosthetic valve-related reintervention will be defined as any surgical or transcatheter intervention performed to treat dysfunction or failure of the implanted study valve. Results will be reported as the number and percentage of participants undergoing valve-related reintervention.

30 days, 6 months, 12 months, and annually through 5 years
Incidence of Bioprosthetic Valve Dysfunction According to VARC-3 Definitions
기간: 30 days, 6 months, 12 months, and annually through 5 years

Bioprosthetic valve dysfunction will be assessed according to Valve Academic Research Consortium 3 (VARC-3) definitions. Bioprosthetic valve dysfunction includes structural valve deterioration, non-structural valve dysfunction, valve thrombosis, and endocarditis. Results will be reported as the number and percentage of participants meeting the criteria for bioprosthetic valve dysfunction and according to the corresponding category.

30 days, 6 months, 12 months, and annually through 5 years
Incidence of Bioprosthetic Valve Failure According to VARC-3 Definitions
기간: 30 days, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months after the index procedure

Bioprosthetic valve failure will be assessed according to Valve Academic Research Consortium 3 (VARC-3) definitions. Results will be reported as the number and percentage of participants meeting the criteria for bioprosthetic valve failure.

30 days, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months after the index procedure

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 11월 1일

기본 완료 (추정된)

2027년 7월 1일

연구 완료 (추정된)

2032년 6월 1일

연구 등록 날짜

최초 제출

2026년 8월 19일

QC 기준을 충족하는 최초 제출

2026년 9월 3일

처음 게시됨 (실제)

2026년 9월 8일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 19일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 16일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다